ProHealth health Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help
Facebook Google Plus
Fibromyalgia  Chronic Fatigue Syndrome & M.E.  Lyme Disease  Natural Wellness  Supplement News  Forums  Our Story
Store     Brands   |   A-Z Index   |   Best Sellers   |   New Products   |   Deals & Specials   |   Under $10   |   SmartSavings Club

Trending News

Meta-analysis adds evidence to association between omega-3 supplementation and lower heart rate

Friendly User's Guide for the Timing of Nutritional Supplements

The Health Benefits of Manuka Honey

Increase Your Magnesium Intake

Vitamin D supplementation could ease IBS symptoms

Top Tips to Boost Your Immunity

11 Amazing Health Benefits of Using Baking Soda

Nicotinamide riboside shows promise for treatment of Alzheimer’s disease

Exercise, calcium, vitamin D, and other factors linked with fewer injurious falls

Mediterranean diet associated with lower risk of aggressive prostate cancer

 
Print Page
Email Article

Promising Alzheimer’s Disease Treatment Suspended

  [ 125 votes ]   [ Discuss This Article ]
www.ProHealth.com • March 18, 2002




Elan Corporation, and Wyeth-Ayerst Laboratories, announced they have decided not to resume further dosing of AN-1792, an experimental immunotherapeutic drug under development for the treatment of mild to moderate Alzheimer’s disease.

In early January, the exploratory Phase 2A study of AN-1792 was suspended immediately after learning that four patients in France were reported to have clinical signs consistent with inflammation in the central nervous system (CNS). Since halting dosing in January, eleven additional patients reported symptoms associated with CNS inflammation.

The researchers, in consultation with the independent Safety Monitoring Committee, have concluded that no additional patients shall be treated with AN-1792, but patients will continue to be followed to assess on-going safety. The companies are continuing their pre-clinical and clinical investigations into these cases and are in regular contact with regulatory agencies in the United States and Europe regarding the progress of this effort.

All patients who experienced brain inflammation, or are, receiving medical care and most have shown improvement or have recovered. The companies are aggressively collaborating with clinical investigators to better understand the cause of this phenomenon.

“We will continue to monitor all patients who have received drug in these studies,” says Dr. Ivan Lieberburg, Elan’s Chief Scientific and Medical Officer. “Our decision to first suspend dosing, and now permanently discontinue dosing in this exploratory phase of clinical research with this single compound, in our opinion, remains in the best interest of the health and safety of patients.”

AN-1792 represents the first in a series of therapeutic approaches currently under development that explore the clinical potential of immunotherapy for Alzheimer’s disease.

“These developments are not uncommon in early clinical research with an innovative compound like AN-1792,” says L. Patrick Gage, President, Wyeth-Ayerst Research.

Clinical trials with AN-1792 were being conducted in the US and four European countries in patients with Alzheimer’s disease using AN-1792 (also known as AIP-001). Approximately 360 patients had received multiple doses of AN-1792.

The Phase 2A study was designed to measure the immune response to immunization with the drug, as well as changes in other parameters in Alzheimer’s patients with mild to moderate disease. The results of this study were expected to provide additional information regarding the immune response to AN-1792, as well as valuable information useful for the design and evaluation of other therapeutic agents being studied in the collaborative development program.



Post a Comment

Featured Products From the ProHealth Store
Optimized Curcumin Longvida® Ultra ATP+, Double Strength Mitochondria Ignite™ with NT Factor®


Article Comments



Be the first to comment on this article!

Post a Comment


 
Optimized Curcumin Longvida with Omega-3

Featured Products

FibroSleep™ FibroSleep™
The All-in-One Natural Sleep Aid
Ultra ATP+, Double Strength Ultra ATP+, Double Strength
Get Energized with Malic Acid & Magnesium
Energy NADH™ 12.5mg Energy NADH™ 12.5mg
Improve Energy & Cognitive Function
Mitochondria Ignite™ with NT Factor® Mitochondria Ignite™ with NT Factor®
Reduce Fatigue up to 45%
Optimized Curcumin Longvida® Optimized Curcumin Longvida®
Supports Cognition, Memory & Overall Health

Natural Remedies

Fatigue & Fibro Fog: Could You Have a B-12 Deficiency? Fatigue & Fibro Fog: Could You Have a B-12 Deficiency?
The Surprising Benefits of Probiotics - What You Didn't Know The Surprising Benefits of Probiotics - What You Didn't Know
Supercharge Your Brain with Two Powerful Nutrients Supercharge Your Brain with Two Powerful Nutrients
Stop Bacteria With Nature's Antibiotics Stop Bacteria With Nature's Antibiotics
Coping When Colds or Flu Catch Up with You Coping When Colds or Flu Catch Up with You

CONTACT US
ProHealth, Inc.
555 Maple Ave
Carpinteria, CA 93013
(800) 366-6056  |  Email

· Become a Wholesaler
· Vendor Inquiries
· Affiliate Program
SHOP WITH CONFIDENCE
Credit Card Processing
SUBSCRIBE TO OUR NEWSLETTERS
Get the latest news about Fibromyalgia, M.E/Chronic Fatigue Syndrome, Lyme Disease and Natural Wellness

CONNECT WITH US ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus

© 2018 ProHealth, Inc. All rights reserved. Pain Tracker App  |  Store  |  Customer Service  |  Guarantee  |  Privacy  |  Contact Us  |  Library  |  RSS  |  Site Map